Motesanib (AMG 706) is an experimental drug candidate originally developed by Amgen but is now being investigated by the Takeda Pharmaceutical Company. It is an orally administered small molecule belonging to angiokinase inhibitor class which acts as an antagonist of VEGF receptors, platelet-derived growth factor receptors, and stem cell factor receptors. It is used as the phosphate salt motesanib diphosphate.

CAS：453562-69-1
中文别名：莫替沙尼;N-(2,3-二氢-3,3-二甲基-1H-吲哚-6-基)-2-[(4-吡啶甲基)氨基]-3-吡啶甲酰胺;3-吡啶甲酰胺,N-(2,3-二氢-3,3-二甲基-1H-吲哚-6-基)-2-[(4-吡啶基甲基)氨基];
英文别名：Motesanib Base;
分子式：C22H23N5O
分子量：373.451
精确质量：373.19
Psa：78.94
Logp：4.3281

MDL号：MFCD10567689

密度：1.251
沸点：517.258ºC at 760 mmHg
折射率：1.669